CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021
November 01 2021 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, announced today that the
company will release its third quarter 2021 financial results after
the market closes on Monday, November 15, 2021. Management will
host a conference call at 5:00 p.m. ET (2:00 p.m. PT) on the same
day to provide an update on the company’s business.
Details for the Conference Call:
Date: November 15, 2021Time: 5:00
p.m. ET (2:00 p.m. PT)
Conference Audio
- Dial-in U.S. and Canada: (844) 825-9789
- Dial-in International: (412) 317-5180
- Conference ID No.: 10161656
For individuals participating in the Investor Call, please call
into the conference audio approximately 10 minutes prior to its
start.
An audio replay of the call will be available beginning at 8:00
p.m. Eastern Time on November 15, 2021, through 11:59 p.m. Eastern
Time on December 6, 2021. To access the recording please dial (844)
512-2921 in the U.S. and Canada, or (412) 317-6671 internationally,
and reference Conference ID# 10161656. The audio recording will
also be available at www.cohbar.com during the same period.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company
focused on the research and development of mitochondria based
therapeutics, an emerging class of drugs for the treatment of
chronic and age-related diseases. Mitochondria based therapeutics
originate from the discovery by CohBar’s founders of a novel group
of naturally occurring mitochondrial-derived peptides within the
mitochondrial genome that regulate metabolism and cell death, and
whose biological activity declines with age. To date, the company
has discovered more than 100 mitochondrial derived peptides and
generated over 1,000 analogs. CohBar’s efforts focus on the
development of these peptides into therapeutics that offer the
potential to address a broad range of diseases, including
nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases,
cancer, acute respiratory distress syndrome (ARDS), type 2
diabetes, and cardiovascular and neurodegenerative diseases. The
company’s lead compound, CB4211, which is under development for the
treatment of NASH and obesity, completed a successful Phase 1a/1b
clinical trial in August 2021. In addition, CohBar has four
preclinical programs, the most advanced of which is CB5138-3, a
peptide with broad anti-fibrotic and anti-inflammatory properties.
This program is currently in IND-enabling studies with the goal of
filing an IND and initiating a First-in-Human study in 2022 with an
initial indication of idiopathic pulmonary fibrosis. The company
also has a program in ARDS, including COVID-19 associated ARDS, as
well as two peptide families with potential utility in treating
various forms of cancer.
For additional company information, please visit
www.cohbar.com.
Contacts:
Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650)
445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024